Evidence map›Paper›PMID 37049856›Full record

ReviewMolecules (Basel, Switzerland)2023

Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options.

Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, Giulio Vistoli, Laura Fumagalli

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Pathophysiology of Maternal Obesity and Hypertension in Pregnancy.Journal of cardiovascular development and disease · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Angelica ArtasensiDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0002-9121-3217
Angelica MazzolariDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0003-1352-1094
Alessandro PedrettiDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0001-5916-2029
Giulio VistoliDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0002-3939-5172
Laura FumagalliDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0003-1917-3000
University of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and type 2 diabetes (T2DM) are major public health concerns associated with serious morbidity and increased mortality. Both obesity and T2DM are strongly associated with adiposopathy, a term that describes the pathophysiological changes of the adipose tissue. In this review, we have highlighted adipose tissue dysfunction as a major factor in the etiology of these conditions since it promotes chronic inflammation, dysregulated glucose homeostasis, and impaired adipogenesis, leading to the accumulation of ectopic fat and insulin resistance. This dysfunctional state can be effectively ameliorated by the loss of at least 15% of body weight, that is correlated with better glycemic control, decreased likelihood of cardiometabolic disease, and an improvement in overall quality of life. Weight loss can be achieved through lifestyle modifications (healthy diet, regular physical activity) and pharmacotherapy. In this review, we summarized different effective management strategies to address weight loss, such as bariatric surgery and several classes of drugs, namely metformin, GLP-1 receptor agonists, amylin analogs, and SGLT2 inhibitors. These drugs act by targeting various mechanisms involved in the pathophysiology of obesity and T2DM, and they have been shown to induce significant weight loss and improve glycemic control in obese individuals with T2DM.

Indexed as

Bariatric SurgeryDiabetes Mellitus, Type 2HumansObesityQuality of LifeWeight Lossadiposopathydiabesityinsulin resistanceobesitytype 2 diabetes mellitus

Identifiers

PMID37049856
PMCPMC10095867
OpenAlexW4362520101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.